Clinical Trials
15 trialsNCT04205812 2026-03-31
POD1UM-304
Incyte Corporation
Phase 3 Active not recruiting
NCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT04035486 2025-10-10
FLAURA2
AstraZeneca
Phase 3 Active not recruiting
NCT05014815 2025-09-16
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 2 Completed
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT02264990 2021-02-26
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
AbbVie
Phase 3 Completed
NCT02259582 2020-09-09
DENALI
Mereo BioPharma
Phase 2 Completed
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT01263782 2019-05-15
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01809210 2018-03-13
SELECT-3
AstraZeneca
Phase 1 Completed
NCT00280748 2017-06-23
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00942825 2017-05-24
CBP08-02
CanBas Co. Ltd.
Phase 2 Completed
NCT00227019 2017-03-06
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Stanford University
Phase 2 Completed
NCT00864513 2015-12-08
Study of Pemetrexed for Second-Line Pancreas Cancer
Georgetown University
Phase 2 Terminated